Canton Hathaway’s AstraZeneca AZN Stock Holding History

Canton Hathaway’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,553	Closed	-$170K	–	257
2020 Q3	$170K	Buy	+1,553	New	+$173K	0.07%	110

Other funds holding AZN

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Canton Hathaway's AZN Position: Q4 2020 in Review

Canton Hathaway sold out of AstraZeneca (AZN) in Q4 2020, closing a stake of 1,553 shares — an estimated $170K sold.

Canton Hathaway first reported a position in AZN in Q3 2020 and held it in 1 quarter. The position peaked at $170K in Q3 2020. 787 funds tracked by Wall St. Rank hold AZN as of Q4 2020.

Canton Hathaway reported no remaining AstraZeneca position as of Q4 2020 after selling out during the quarter.
Canton Hathaway sold 1,553 AstraZeneca shares in Q4 2020, an estimated $170K.
Canton Hathaway first reported a position in AstraZeneca in Q3 2020 and held it in 1 quarter.
Canton Hathaway's AstraZeneca position peaked at $170K in Q3 2020.
787 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2020.

Based on Canton Hathaway's 13F filing for Q4 2020, filed 3 Feb 2021.